A
EFTR

Abingworth’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Abingworth’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.06M Hold
192,885
– – 0.67% 12
2022
Q3 		$2.73M Hold
192,885
– – 0.93% 10
2022
Q2 		$6.46M Hold
192,885
– – 2.07% 9
2022
Q1 		$18.9M Hold
192,885
– – 5.36% 7
2021
Q4 		$39.9M Hold
192,885
– – 9.67% 4
2021
Q3 		$67M Buy
+192,885
New +$62.2M 15.21% 2

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
ECM
Evolution Capital Management Crystal Bay, Nevada $29M AUM 2.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Abingworth's EFTR Position: Q4 2022 in Review

Abingworth held its eFFECTOR Therapeutics, Inc. Common Stock (EFTR) position steady in Q4 2022 at 192,885 shares worth $2.06M. The position accounts for 0.67% of the portfolio, ranked #12.

Abingworth first reported a position in EFTR in Q3 2021 and has held it in 6 quarters since. The position peaked at $67M in Q3 2021. 30 funds tracked by Wall St. Rank hold EFTR as of Q4 2022.

  • Abingworth held 192,885 shares of eFFECTOR Therapeutics, Inc. Common Stock worth $2.06M as of Q4 2022.
  • Abingworth left its eFFECTOR Therapeutics, Inc. Common Stock share count unchanged in Q4 2022.
  • eFFECTOR Therapeutics, Inc. Common Stock made up 0.67% of Abingworth's portfolio in Q4 2022, its #12 holding.
  • Abingworth first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q3 2021 and has held it in 6 quarters since.
  • Abingworth's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $67M in Q3 2021.
  • 30 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.